New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export MRK’s income statement to Excel — free account
Merck & Co., Inc.
MRKHealthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −12.1%
- Free cash flow
- −19.3%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
134.95
2.21
+1.66%
Follow MRK
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow of $5.5B covered $2.5B of dividends and buybacks. Cash rose by $2.8B. What is a cash flow statement?
- Free cash flow
- $5.5B 84.1% of operating cash flow
- Returned to shareholders
- $2.5B 45.4% of free cash flow
- Debt, net
- $0.00 borrowed
- Change in cash
- +$2.8B over the period
| Operating cash flow | 6.6 |
|---|---|
| Capital expenditures | −1.0 |
| Free cash flow | 5.5 |
| Acquisitions, net | −0.6 |
| From investments, net | +0.4 |
| Dividends | −2.1 |
| Buybacks, net | −0.4 |
| Other | 0.0 |
| Change in cash | 2.8 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $2.9B | $3.9B | $5.4B | $6.6B |
| Capex | −$1.0B | −$991M | −$893M | −$1.0B |
| Free cash flow | $1.8B | $2.9B | $4.5B | $5.5B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
5,067.00 | (1,337.00) | (4,243.00) | 2,962.00 |
+8 more quarters Free account |
Depreciation & Amortization |
1,783.00 | 1,583.00 | 1,512.00 | 2,466.00 | |
Non Cash Items (Other) |
(643.00) | 4,782.00 | 8,242.00 | (370.00) | |
Change in other assets and liabilities |
71.00 | 423.00 | (1,613.00) | 1,545.00 | |
Other operating activities |
280.00 | (81.00) | 20.00 | 118.00 | |
Operating Cash Flow |
6,558.00 | 5,370.00 | 3,918.00 | 2,857.00 | |
Capital expenditures |
(1,040.00) | (893.00) | (991.00) | (1,033.00) | |
Net Aquisitions |
(630.00) | (5,842.00) | (8,779.00) | (10,042.00) | |
Short Term Investments Change (Net) |
405.00 | 1,155.00 | (374.00) | 46.00 | |
Other investing activities |
(54.00) | (22.00) | (66.00) | (172.00) | |
Investing cash flow |
(1,319.00) | (5,602.00) | (10,210.00) | (11,201.00) | |
Repayment/Issuance of Debt (Net) |
0.00 | 4,890.00 | (79.00) | 7,916.00 | |
Equity Repurchase (Common, Net) |
(406.00) | (714.00) | (717.00) | (1,205.00) | |
Dividends Paid (Total) |
(2,099.00) | (2,144.00) | (2,105.00) | (2,018.00) | |
Other financial activities |
73.00 | (270.00) | (80.00) | 58.00 | |
Financing cash flow |
(2,432.00) | 1,762.00 | (2,981.00) | 4,751.00 | |
Exchange Rate Adjustment |
(46.00) | (37.00) | (19.00) | 23.00 | |
Change in Cash |
2,761.00 | 1,493.00 | (9,292.00) | (3,570.00) | |
Beginning Cash |
0.00 | 0.00 | 14,690.00 | 0.00 | |
Ending Cash |
2,761.00 | 1,493.00 | 5,398.00 | (3,570.00) | |
Stock Based Compensation |
369.00 | 298.00 | 185.00 | 205.00 | |
Dividends Paid (Common) |
(2,099.00) | (2,144.00) | (2,105.00) | (2,018.00) | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
71.00 | 423.00 | (1,613.00) | (2,319.00) | |
Investments Change (Net) |
405.00 | 1,155.00 | (374.00) | 46.00 | |
Issuance/Purchase of Shares |
(406.00) | (714.00) | (717.00) | (1,205.00) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026